RECQL4 affects MHC class II‐mediated signalling and favours an immune‐evasive signature that limits response to immune checkpoint inhibitor therapy in patients with malignant melanoma

Sara Egea‐Rodriguez(West German Heart and Vascular Center Essen), Iris Helfrich(German Cancer Research Center)
Clinical and Translational Medicine
January 1, 2025
Cited by 2


Related Papers